ProUroCare Medical Inc. PUMD

Company Overview

ProUroCare Medical Inc. (OTC: PUMD) was a medical technology company focused on the detection and management of prostate disease, particularly prostate cancer. The company operated within the urology and diagnostic medical device industries and was primarily known for developing technologies intended to improve prostate examination accuracy and support earlier clinical detection. Public filings and historical investor materials identify the company’s principal commercial focus as the development and commercialization of its prostate diagnostic platform.

The company’s primary product platform was the ProUroScan system, a computer-assisted diagnostic device designed to enhance the traditional digital rectal examination through pressure-sensing technology and imaging analytics. ProUroCare positioned its technology as a non-invasive adjunct tool for physicians treating patients with elevated prostate cancer risk or abnormal screening results. Historically, the company evolved from an early-stage medical device developer into a commercialization-focused organization seeking regulatory adoption and broader physician utilization. Data regarding recent operating scale and commercialization progress is inconclusive based on available public sources.